Editing Iowa Mutation Modeling Program

== Iowa Mutation Modeling Program ==
'''Mutation:''' Aβ Asp23Asn  
'''Objective:''' Determine whether mutation-specific changes in aggregation kinetics are sufficient to explain altered amyloid deposition patterns and clinical onset timing.

----

=== 1. Biological Background ===

==== 1.1 Genetic and Molecular Context ====
* Description of the Asp23Asn substitution
* Location within Aβ sequence
* Known biochemical effects (e.g., altered charge, isomerization propensity)

==== 1.2 Reported Phenotypic Features ====
* Age of onset distribution
* Neuropathological characteristics
* Reported fibril properties
* Relevant clinical observations

----

=== 2. Working Mechanistic Hypothesis ===

Precise statement of the causal claim under investigation.

Example structure:

* The Asp23Asn mutation alters local electrostatic interactions.
* This increases fibril thermodynamic stability.
* Increased stability modifies aggregation kinetics (nucleation, elongation, secondary nucleation).
* Altered kinetics propagate to macroscopic plaque accumulation dynamics.

Clearly distinguish:
* Assumptions
* Empirical constraints
* Open uncertainties

----

=== 3. Mathematical Formalization ===

==== 3.1 Aggregation Kinetics Model ====
* Governing equations (e.g., nucleation–elongation framework)
* Definition of state variables
* Rate constants
* Conservation constraints

==== 3.2 Mutation-Specific Modifications ====
* Which parameters differ from wild-type?
* Justification for parameter changes
* Sensitivity to parameter variation

==== 3.3 Assumptions and Simplifications ====
* Spatial homogeneity vs heterogeneity
* Deterministic vs stochastic treatment
* Boundary conditions

----

=== 4. Parameterization ===

Structured parameter table:

{| class="wikitable"
! Parameter !! Symbol !! Value !! Source !! Experimental Context
|-
| Primary nucleation rate || k_n || ... || ... || in vitro aggregation assay
|-
| Elongation rate || k_+ || ... || ... || ...
|-
| Secondary nucleation rate || k_2 || ... || ... || ...
|}

Include:
* Units
* Measurement uncertainty
* Scaling assumptions (in vitro → in vivo)

----

=== 5. Scaling Strategy ===

How molecular kinetics propagate upward.

==== 5.1 From Aggregates to Plaque Load ====
* Mapping monomer/polymer concentration to plaque mass
* Spatial assumptions

==== 5.2 From Plaque Load to Imaging Signal ====
* Relationship to PET SUVR
* Assumed conversion functions

==== 5.3 From Plaque Accumulation to Clinical Onset ====
* Threshold hypotheses
* Network vulnerability assumptions

Explicitly state which links are empirical vs theoretical.

----

=== 6. Quantitative Predictions ===

Clearly enumerated, falsifiable predictions:

* Predicted shift in age of detectable amyloid PET signal
* Predicted plaque growth rate differences vs wild-type
* Predicted regional deposition differences
* Sensitivity of onset timing to kinetic parameters

Avoid vague language. Use numerical ranges where possible.

----

=== 7. Comparison with Existing Data ===

* PET studies in Iowa mutation carriers
* Reported onset ages
* Neuropathological findings

Explicitly state:
* Agreement
* Discrepancies
* Unexplained features

----

=== 8. Sensitivity and Identifiability Analysis ===

* Which parameters dominate model behavior?
* Are multiple parameter combinations indistinguishable?
* Which measurements would most constrain uncertainty?

This section signals modeling seriousness.

----

=== 9. Open Problems ===

* Missing kinetic measurements
* In vivo vs in vitro scaling uncertainties
* Spatial heterogeneity
* Interaction with tau pathology

----

=== 10. Next Steps ===

* Required data
* Computational refinement
* Proposed experimental collaborations